Leerink Partners Lowers FY2028 Earnings Estimate for Inspire Medical Systems

Investment analysts at Leerink Partners have revised their earnings per share (EPS) estimates for Inspire Medical Systems, Inc. (NYSE: INSP) concerning the fiscal year 2028. In a report published on February 11, analyst M. Kratky adjusted the estimate downward to $5.62, a slight decrease from the previous estimate of $5.69. For the current fiscal year, analysts expect Inspire Medical Systems to achieve an EPS of $1.33.

Other analysts have also had notable input on Inspire Medical Systems. Morgan Stanley revised its target price for the shares, lowering it from $230.00 to $220.00 while maintaining an "overweight" rating. Similarly, Truist Financial decreased their target price from $250.00 to $235.00, continuing a "buy" rating on the stock. In a more optimistic move, Bank of America upgraded Inspire Medical from a "neutral" rating to a "buy" rating, with their price target increasing from $220.00 to $255.00. Additionally, Robert W. Baird decreased their target from $252.00 to $248.00 while keeping an "outperform" rating. KeyCorp also maintained an "overweight" rating, adjusting their target down slightly from $236.00 to $234.00.

At present, the consensus among analysts shows that three have rated the stock as holding, while eight rated it as a buy. Based on MarketBeat data, Inspire Medical Systems has an average rating of "Moderate Buy" and a consensus price target set at $228.82.

Inspire Medical Systems Stock Performance

As of Wednesday, stocks for Inspire Medical Systems opened at $183.17. The company displays a 50-day moving average price of $189.39 and a 200-day moving average price of $191.39. The stock has experienced a 52-week low of $123.00 and a high of $257.40, with a market capitalization of approximately $5.49 billion, a price-to-earnings (PE) ratio of 171.18, and a beta of 1.32.

On February 10, Inspire Medical Systems released their quarterly earnings, reporting an EPS of $1.15, significantly exceeding the consensus estimate of $0.74 by $0.41. The company's return on equity stands at 5.30%, along with a net margin of 4.37%.

Institutional Investor Activity

Recent activity among large investors affecting Inspire Medical Systems includes several changes to their holdings. WINTON GROUP Ltd increased their stake by 15.6% in the fourth quarter, acquiring an additional 806 shares for a total of 5,977 shares valued at $1,108,000. Vanguard Group Inc. grew their holdings by 1.2%, now owning 3,270,357 shares worth $606,259,000 after acquiring an extra 38,219 shares. Other institutional movements include KLP Kapitalforvaltning AS purchasing new stakes and Sei Investments Co. increasing their position by 27.7% with an additional 35,486 shares, totaling 163,474 shares valued at $30,305,000. American Century Companies Inc. also raised their investment by 66.9%, ending up with 11,214 shares valued at $2,079,000.

Overall, institutional investors hold a significant 94.91% of Inspire Medical Systems' stock.

Company Overview

Inspire Medical Systems, Inc. is a medical technology firm dedicated to the development and commercialization of minimally invasive solutions targeted at patients suffering from obstructive sleep apnea (OSA). Its primary product is the Inspire system, a neurostimulation technology designed to offer a safe and effective treatment for those with moderate to severe OSA.

As the investment community closely monitors Inspire Medical Systems, fluctuations in earnings estimates and stock performance will continue to be closely watched in the coming years.

earnings, stocks, estimates